keyword
MENU ▼
Read by QxMD icon Read
search

Tumor Pseudoprogression

keyword
https://www.readbyqxmd.com/read/30334063/-tumor-assessment-in-immune-checkpoint-inhibitor-therapy-tumor-response-progression-and-pseudoprogression
#1
REVIEW
S Foller, H Oppel-Heuchel, M-O Grimm
In contrast to chemotherapy, treatment with immune checkpoint inhibitors occasionally results in an unconventional pattern of response. Besides an early partial or complete response or tumor progression, a so-called pseudoprogression, a "mixed response" or late responses can also be observed. Treatment beyond radiographically defined progression may therefore be appropriate in selected cases. For these treatment decisions, the clinical evaluation of the patient (performance status, symptoms, etc...
October 17, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/30328672/hyperprogressive-disease-in-patients-with-non-small-cell-lung-cancer-treated-with-nivolumab-a-case-series
#2
Masaki Kanazu, Ryuya Edahiro, Hiroyuki Krebe, Kohei Nishida, Mikako Ishijima, Takeshi Uenami, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori
Nivolumab is an anti-PD-1 blocking monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). However, some patients on immunotherapy may experience rapid progression and worsening clinical status, known as hyperprogressive disease. We retrospectively reviewed the clinical records of patients with NSCLC administered nivolumab therapy at Toneyama National Hospital, Japan, from January 2016 to January 2018. Of the 87 patients administered nivolumab therapy, five experienced rapid progression during one cycle of nivolumab therapy...
October 17, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/30307035/association-between-soluble-immune-mediators-and-tumor-responses-in-patients-with-non-small-cell-lung-cancer-treated-with-anti-pd-1-inhibitor
#3
Norikazu Matsuo, Koichi Azuma, Satoshi Hattori, Junya Ohtake, Akihiko Kawahara, Hidenobu Ishii, Takaaki Tokito, Kazuhiko Yamada, Yuji Shibata, Tadasuke Shimokawaji, Tetsuro Kondo, Terufumi Kato, Haruhiro Saito, Kouzo Yamada, Tetsuro Sasada, Tomoaki Hoshino
Although programmed death (PD)-1 immune checkpoint therapies target the immune system, the relationship between inflammatory factors and the clinical outcome of anti-PD-1 therapy for non-small cell lung cancer (NSCLC) is not fully understood. Here we examined the association between soluble immune mediators and the outcome of treatment with PD-1 inhibitors in patients with advanced/recurrent NSCLC. In two independent cohorts, we assessed the levels of 88 different soluble immune mediators in peripheral blood before and after anti-PD-1 treatment, and evaluated their associations with clinical outcomes...
October 11, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/30292263/ct-response-patterns-and-the-role-of-ct-textural-features-in-inoperable-abdominal-retroperitoneal-soft-tissue-sarcomas-treated-with-trabectedin
#4
Michael Esser, Cristopher Kloth, Wolfgang Maximilian Thaiss, Christian Philipp Reinert, Jan Fritz, Hans-Georg Kopp, Marius Horger
PURPOSE: To evaluate CT patterns and textural features of soft tissue sarcomas following trabectedin therapy as well as their suitability for predicting therapeutic response. MATERIAL AND METHODS: A total of 31 patients (18 female, 13 male; mean age, 58.0years; range, 38-79years) with sarcoma under trabectedin as a third-line therapy between October 2008 and July 2017 underwent baseline and follow-up contrast-enhanced CT. Response evaluation was based on modifiedCHOI-criteria and RECIST1...
October 2018: European Journal of Radiology
https://www.readbyqxmd.com/read/30275788/advances-in-neuro-oncology-imaging-techniques
#5
REVIEW
Brannan E O'Neill, Christian B Hochhalter, Christopher Carr, Michael J Strong, Marcus L Ware
Background: Central nervous system (CNS) tumors are a rare but devastating malignancy, often robbing patients of the basic quality of life. Despite advances in our understanding of the CNS tumor disease processes, the prognosis for patients with CNS tumors remains poor. Better characterization and diagnostic and monitoring approaches are necessary to assist in diagnosis and treatment of CNS tumors. One important tool in the neuro-oncology armamentarium is the use of advanced imaging techniques...
2018: Ochsner Journal
https://www.readbyqxmd.com/read/30253794/response-to-pd1-inhibition-in-conventional-chondrosarcoma
#6
Michael J Wagner, Robert W Ricciotti, Jose Mantilla, Elizabeth T Loggers, Seth M Pollack, Lee D Cranmer
BACKGROUND: Chondrosarcoma is one of the most common malignant bone tumors in adults. Conventional chondrosarcoma represents around 85% of all chondrosarcomas and is notoriously difficult to treat with chemotherapy. CASE PRESENTATION: We describe a 67-year-old man with metastatic conventional chondrosarcoma who was treated with nivolumab. Treatment was discontinued after restaging showed increased tumor burden, which later proved to be pseudoprogression. The patient restarted nivolumab and continues to have a near complete response...
September 25, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/30253080/pleural-or-pericardial-metastasis-a-significant-factor-affecting-efficacy-and-adverse-events-in-lung-cancer-patients-treated-with-pd-1-pd-l1-inhibitors
#7
Da Hyun Kang, Chaeuk Chung, Ju-Ock Kim, Sung Soo Jung, Hee Sun Park, Dong Il Park, Sun Young Jung, Myoungrin Park, Jeong Eun Lee
BACKGROUND: Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because of hyperprogression and pseudoprogression. The aim of this study was to investigate the factors associated with tumor response and serious outcomes. METHODS: We retrospectively collected the medical records of 51 patients with advanced NSCLC who received PD-1/PD-L1 inhibitors between January 2016 and February 2018...
September 25, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/30253076/diffuse-alveolar-hemorrhage-with-pseudoprogression-during-nivolumab-therapy-in-a-patient-with-malignant-melanoma
#8
Takaya Ikeda, Hiroyuki Yamaguchi, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyoutoku, Hiroaki Senju, Noriho Sakamoto, Satoshi Iwanaga, Yutaka Kuwatsuka, Minoru Fukuda, Hiroshi Mukae
Nivolumab, an anti-PD-1 antibody, has been shown to be effective in many cancers, such as malignant melanoma and lung cancer; however, nivolumab therapy can result in pseudoprogression. Diffuse alveolar hemorrhage (DAH) is persistent or recurrent pulmonary hemorrhage as a result of drugs, autoimmune diseases, or infections. DAH with pseudoprogression during nivolumab administration has rarely been reported. Herein, we describe our experience with one such case. A 41-year-old woman exhibited bloody sputum and ground glass opacities in the lungs along with tumor growth during nivolumab therapy for multiple lung metastases of malignant melanoma...
September 25, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/30236027/immunotherapy-beyond-progression-in-advanced-renal-cell-carcinoma-a-case-report-and-review-of-the-literature
#9
Sara Elena Rebuzzi, Giacomo Bregni, Massimiliano Grassi, Azzurra Damiani, Michele Buscaglia, Sebastiano Buti, Giuseppe Fornarini
Immunotherapy is associated with different response patterns compared with chemotherapy and targeted therapy, including delayed response and stabilization after progression (pseudoprogression). According to new immuno-based response criteria, immunotherapy can be continued after radiological progression when a clinical benefit is observed. We report a case of an advanced renal cell carcinoma patient treated with nivolumab, who developed clinical benefit and delayed radiological response after initial progression...
September 2018: Immunotherapy
https://www.readbyqxmd.com/read/30231380/patterns-of-response-and-progression-to-immunotherapy
#10
Edith Borcoman, Amara Nandikolla, Georgina Long, Sanjay Goel, Christophe Le Tourneau
Patterns of response and progression to immunotherapy may differ from those observed with drugs such as chemotherapy and molecularly targeted agents. Specifically, some patients experience a response after progression that is retrospectively named pseudoprogression. This phenomenon of pseudoprogression, first reported in patients with melanoma who were treated with ipilimumab, has led to the development of immune-specific related response criteria, such as irRC (immune-related response criteria), irRECIST (immune-related RECIST), and iRECIST (immunotherapy RECIST) that allow continued treatment beyond progression...
May 23, 2018: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/30220316/radiologic-predictors-of-immune-checkpoint-inhibitor-response-in-advanced-head-and-neck-squamous-cell-carcinoma
#11
Vishwajith Sridharan, Rifaquat M Rahman, Raymond Y Huang, Nicole G Chau, Jochen H Lorch, Ravindra Uppaluri, Robert I Haddad, Glenn J Hanna, Jonathan D Schoenfeld
Radiologic predictors of response to immune checkpoint blockade (ICPi) in advanced head and neck squamous cell carcinoma (HNSCC) patients could help guide patient selection and management. We analyzed a large institutional cohort of 100 consecutive HNSCC patients treated with ICPi to investigate associations between molecular and radiologic phenotype and assess radiologic predictors of response and survival. Of particular interest was the impact of increased total tumor burden (TB), calculated as the sum of the largest diameter of all measurable lesions according to RECIST 1...
October 2018: Oral Oncology
https://www.readbyqxmd.com/read/30215111/current-concepts-and-challenges-in-the-radiologic-assessment-of-brain-tumors-in-children-part-2
#12
REVIEW
Benita Tamrazi, Kshitij Mankad, Marvin Nelson, Felice D'Arco
Assessing tumor response is a large part of everyday clinical work in neuroradiology. However in the setting of tumor treatment, distinguishing tumor progression from treatment-related changes is difficult on conventional MRI sequences. This is made even more challenging in children where mainstay advanced imaging techniques that are often used to decipher progression versus treatment-related changes have technical limitations. In this review, we highlight the challenges in pediatric neuro-oncologic tumor assessment with discussion of pseudophenomenon including pseudoresponse and pseudoprogression...
September 13, 2018: Pediatric Radiology
https://www.readbyqxmd.com/read/30193240/hyperprogressive-disease-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-pd-1-pd-l1-inhibitors-or-with-single-agent-chemotherapy
#13
Roberto Ferrara, Laura Mezquita, Matthieu Texier, Jihene Lahmar, Clarisse Audigier-Valette, Laurent Tessonnier, Julien Mazieres, Gerard Zalcman, Solenn Brosseau, Sylvestre Le Moulec, Laura Leroy, Boris Duchemann, Corentin Lefebvre, Remi Veillon, Virginie Westeel, Serge Koscielny, Stephane Champiat, Charles Ferté, David Planchard, Jordi Remon, Marie-Eve Boucher, Anas Gazzah, Julien Adam, Emilio Bria, Giampaolo Tortora, Jean-Charles Soria, Benjamin Besse, Caroline Caramella
Importance: Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in advanced non-small cell lung cancer (NSCLC) are unknown. Objectives: To investigate whether HPD is observed in patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors compared with single-agent chemotherapy and whether there is an association between treatment and HPD...
September 6, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30107606/incorporating-diffusion-and-perfusion-weighted-mri-into-a-radiomics-model-improves-diagnostic-performance-for-pseudoprogression-in-glioblastoma-patients
#14
Jung Youn Kim, Ji Eun Park, Youngheun Jo, Woo Hyun Shim, Soo Jung Nam, Jeong Hoon Kim, Roh-Eul Yoo, Seung Hong Choi, Ho Sung Kim
Background: Pseudoprogression is a diagnostic challenge in early post-treatment glioblastoma. We therefore developed and validated a radiomics model using multiparametric MRI to differentiate pseudoprogression from early tumor progression in patients with glioblastoma. Methods: The model was developed from the enlarging contrast-enhancing portions of 61 glioblastomas within 3 months after standard treatment with 6472 radiomic features being obtained from contrast-enhanced T1-weighted imaging, fluid-attenuated inversion recovery imaging, and apparent diffusion coefficient (ADC), and cerebral blood volume (CBV) maps...
August 11, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/30094640/glioblastoma-radiomics-can-genomic-and-molecular-characteristics-correlate-with-imaging-response-patterns
#15
Michael H Soike, Emory R McTyre, Nameeta Shah, Ralph B Puchalski, Jordan A Holmes, Anna K Paulsson, Lance D Miller, Christina K Cramer, Glenn J Lesser, Roy E Strowd, William H Hinson, Ryan T Mott, Annette J Johnson, Hui-Wen Lo, Adrian W Laxton, Stephen B Tatter, Waldemar Debinski, Michael D Chan
PURPOSE: For glioblastoma (GBM), imaging response (IR) or pseudoprogression (PSP) is frequently observed after chemoradiation and may connote a favorable prognosis. With tumors categorized by the Cancer Genome Atlas Project (mesenchymal, classical, neural, and proneural) and by methylguanine-methyltransferase (MGMT) methylation status, we attempted to determine if certain genomic or molecular subtypes of GBM were specifically associated with IR or PSP. METHODS: Patients with GBM treated at two institutions were reviewed...
October 2018: Neuroradiology
https://www.readbyqxmd.com/read/30053725/hyperprogression-as-a-distinct-outcome-after-immunotherapy
#16
REVIEW
J Fuentes-Antrás, M Provencio, E Díaz-Rubio
Cancer research is living a time of unparalleled expectations around immunotherapy, a therapeutic strategy that materializes the elegant idea of weaponizing our immune system to eradicate tumor cells. In an everchanging standard of care, a growing number of studies have shown that immunotherapy may accelerate tumor progression in a significant subset of patients ranging from 4% to 29% across multiple histologies. The identification of hyperprogression poses a challenge for RECIST criteria, which fail to capture pre- and post-treatment tumor growth kinetics at early times of disease...
July 18, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29991973/pseudoprogression-of-cns-metastatic-disease-of-alveolar-soft-part-sarcoma-during-anti-pdl1-treatment
#17
Thomas A Vander Jagt, Lara E Davis, Meghna Das Thakur, Carl Franz, Jeffery M Pollock
Immune checkpoint inhibitors are increasingly used in treatment of metastatic renal cell carcinoma, melanoma, and nonsmall cell lung cancer, as well as in clinical trials for novel targets. We present a pediatric patient with metastatic alveolar soft part sarcoma who was treated with MPDL3280 (Atezolizumab), a monoclonal anti-programmed death ligand-1 antibody. Imaging results for the patient suggested disease progression of multiple brain metastases with stable systemic disease. The patient met response evaluation criteria in solid tumors (RECIST) criteria of progression of disease and was removed from treatment with MPDL3280...
August 2018: Radiology Case Reports
https://www.readbyqxmd.com/read/29988633/pulmonary-pleomorphic-carcinoma-with-pseudoprogression-during-nivolumab-therapy-and-the-usefulness-of-tumor-markers-a-case-report
#18
Akihiro Yoshimura, Chieko Takumi, Taisuke Tsuji, Ryosuke Hamashima, Shinsuke Shiotsu, Tatsuya Yuba, Yoji Urata, Noriya Hiraoka
Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70-year-old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragment levels decreased. Serum tumor marker might help to distinguish pseudoprogression.
July 2018: Clinical Case Reports
https://www.readbyqxmd.com/read/29983829/pitfalls-in-the-radiological-response-assessment-of-immunotherapy
#19
REVIEW
Lucian Beer, Maximilian Hochmair, Helmut Prosch
Immunotherapies comprise of a class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, and Hodgkin's lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization criteria...
2018: Memo
https://www.readbyqxmd.com/read/29978949/well-controlled-pleural-effusion-indicated-pseudoprogression-after-immunotherapy-in-lung-cancer-a-case-report
#20
Guihong Liu, Tao Chen, Ronghui Li, Li Zhu, Dingyi Liu, Zhenyu Ding
Squamous cancer (SqCC) of the lung has a poor prognosis. With the advent of immunotherapy, prognosis has tended to improve; however, pseudoprogression poses a challenge to the management of immunotherapy. Herein, we discuss the case of a 47-year-old heavy smoker with advanced SqCC. The patient had recurrent disease after initial successful control of the tumor by concurrent radiochemotherapy, together with ample pleural effusion. Pleural effusion was well controlled with systematic nivolumab and intra-thoracic recombinant endostatin; however with simultaneous deterioration of performance and tumor progression...
September 2018: Thoracic Cancer
keyword
keyword
170366
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"